Agilent Technologies, Inc. (NYSE:A) Holdings Lowered by Liontrust Investment Partners LLP

Liontrust Investment Partners LLP lowered its stake in Agilent Technologies, Inc. (NYSE:A) by 0.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 989,200 shares of the medical research company’s stock after selling 2,300 shares during the quarter. Agilent Technologies makes up 2.0% of Liontrust Investment Partners LLP’s investment portfolio, making the stock its 22nd largest holding. Liontrust Investment Partners LLP owned about 0.33% of Agilent Technologies worth $136,846,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Financial Gravity Asset Management Inc. purchased a new stake in shares of Agilent Technologies in the first quarter worth approximately $2,108,000. Gitterman Wealth Management LLC acquired a new position in Agilent Technologies in the 1st quarter valued at approximately $266,000. Mirova lifted its position in Agilent Technologies by 24.7% in the 1st quarter. Mirova now owns 4,483 shares of the medical research company’s stock worth $620,000 after buying an additional 888 shares in the last quarter. Ossiam boosted its stake in shares of Agilent Technologies by 5.8% during the 1st quarter. Ossiam now owns 16,387 shares of the medical research company’s stock valued at $2,267,000 after buying an additional 903 shares during the period. Finally, Seven Eight Capital LP purchased a new position in shares of Agilent Technologies during the 1st quarter valued at $485,000.

Analysts Set New Price Targets

A has been the topic of a number of recent research reports. 58.com restated a “maintains” rating on shares of Agilent Technologies in a research note on Wednesday, May 24th. Jefferies Financial Group dropped their price objective on Agilent Technologies from $150.00 to $146.00 and set a “buy” rating on the stock in a report on Wednesday, August 16th. Robert W. Baird reduced their target price on shares of Agilent Technologies from $144.00 to $140.00 and set an “outperform” rating for the company in a research note on Wednesday, August 16th. Wells Fargo & Company decreased their target price on shares of Agilent Technologies from $170.00 to $160.00 and set an “overweight” rating for the company in a research report on Wednesday, May 24th. Finally, Barclays cut their price target on shares of Agilent Technologies from $115.00 to $110.00 and set an “underweight” rating on the stock in a report on Wednesday, August 16th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, Agilent Technologies has a consensus rating of “Moderate Buy” and a consensus price target of $148.12.

Agilent Technologies Price Performance

Shares of Agilent Technologies stock traded down $2.27 during mid-day trading on Friday, reaching $113.99. 1,789,767 shares of the stock were exchanged, compared to its average volume of 1,589,428. Agilent Technologies, Inc. has a fifty-two week low of $113.28 and a fifty-two week high of $160.26. The company has a market cap of $33.35 billion, a price-to-earnings ratio of 29.83, a price-to-earnings-growth ratio of 2.15 and a beta of 1.03. The firm has a 50-day simple moving average of $122.08 and a 200 day simple moving average of $127.64. The company has a current ratio of 2.29, a quick ratio of 1.71 and a debt-to-equity ratio of 0.49.

Agilent Technologies (NYSE:A) last posted its quarterly earnings data on Tuesday, August 15th. The medical research company reported $1.43 earnings per share for the quarter, topping the consensus estimate of $1.36 by $0.07. The company had revenue of $1.67 billion during the quarter, compared to analyst estimates of $1.66 billion. Agilent Technologies had a net margin of 16.20% and a return on equity of 29.86%. The company’s revenue was down 2.7% on a year-over-year basis. During the same quarter last year, the business posted $1.34 earnings per share. On average, sell-side analysts predict that Agilent Technologies, Inc. will post 5.42 EPS for the current fiscal year.

Insider Transactions at Agilent Technologies

In other Agilent Technologies news, CEO Michael R. Mcmullen sold 944 shares of the firm’s stock in a transaction dated Thursday, July 27th. The shares were sold at an average price of $130.00, for a total value of $122,720.00. Following the completion of the sale, the chief executive officer now owns 260,869 shares in the company, valued at approximately $33,912,970. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, VP Rodney Gonsalves sold 3,500 shares of Agilent Technologies stock in a transaction dated Wednesday, August 23rd. The stock was sold at an average price of $118.78, for a total value of $415,730.00. Following the completion of the sale, the vice president now directly owns 24,219 shares in the company, valued at $2,876,732.82. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Michael R. Mcmullen sold 944 shares of the stock in a transaction on Thursday, July 27th. The shares were sold at an average price of $130.00, for a total value of $122,720.00. Following the completion of the transaction, the chief executive officer now directly owns 260,869 shares in the company, valued at approximately $33,912,970. The disclosure for this sale can be found here.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies.